Ablynx
- Company typePrivate
- Founded2001
- HeadquartersZwijnaarde, Belgium
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Ablynx firmographics
Firmographics- Name
- Ablynx
- Legal name
- Ablynx N.V.
- Website
- https://ablynx.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Ablynx industry classification
Industry- Product category
- Biopharmaceuticals / Nanobody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Nanobodies & Alternative Antibody Scaffolds (HLAAAAAG)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Ablynx is headquartered
LocationHeadquarters
- HQ city
- Zwijnaarde
- HQ country
- Belgium
- HQ region
- Europe
Markets served
Ablynx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Ablynx product offering
Product offeringCore offering
Ablynx developed and commercialized the proprietary NANOBODY® technology platform, a single-domain antibody fragment technology derived from heavy-chain only antibodies found in camelids (camels, llamas, alpacas) and sharks. The platform enables the engineering of multivalent nanobody molecules that can bind multiple therapeutic targets at once, supporting development of orally bioavailable treatments for immune-mediated diseases (e.g., chronic immune thrombocytopenia) and oncology, including bispecific constructs that bridge tumor cells with immune cells.
Product overview
Ablynx developed the NANOBODY® Technology Platform, a proprietary platform for creating nanobody-based therapeutics. NANOBODY molecules are small protein fragments derived from heavy-chain-only antibodies found in species such as camels, llamas, alpacas, and sharks. The technology enables the creation of multivalent NANOBODY molecules that can bind to multiple targets simultaneously, allowing for complex therapeutic approaches including bridging tumor and immune cells. The platform supports oral administration of therapeutics, potentially reducing invasiveness of treatments. Ablynx N.V. holds the registered trademark for NANOBODY, and the technology is now part of Sanofi's portfolio following acquisition.
Differentiator
Problem solved
Functional benefit
Products and services
- NANOBODY® Technology Platform Proprietary platform for engineering single-domain antibody fragments (NANOBODY molecules) derived from heavy-chain only antibodies of camelids and sharks. Enables the creation of multivalent nanobody compounds that can simultaneously bind multiple targets, including bispecific constructs that bridge tumor cells and immune cells for cancer immunotherapy, with oral administration potential. Used by Ablynx (and now Sanofi) to develop therapeutics for immune-mediated diseases such as chronic immune thrombocytopenic purpura and for oncology applications.
Companies that use Ablynx
Customer profileSegments1 record
Ideal customer profiles2 records
Ablynx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ablynx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SanoficoreSanofi acquired Ablynx and now leverages the NANOBODY® technology platform for drug discovery and development. The technology has been integrated into Sanofi's broader therapeutic development capabilities, combining NANOBODY molecules with Sanofi's large-scale manufacturing capacity to develop next-generation medicines.
Recent moves6 records
Expansion highlights4 records
Ablynx competitors and assessment
Company assessmentDirect peers
- argenx: argenx is the closest direct peer to Ablynx, developing efgartigimod and other therapeutics based on its proprietary Fc-based antibody fragment technology derived from llama-derived single-domain antibodies (the VHH platform). Both companies pioneered single-domain antibody therapeutics and target immunology indications.
- Genmab: Genmab develops bispecific and multispecific antibody therapeutics using its proprietary DuoBody and HexaBody platforms. It competes with Ablynx in creating next-generation antibody-based therapeutics capable of multi-target engagement for oncology and immunology indications.
Broad incumbents
- AstraZeneca: AstraZeneca is a large biopharma incumbent operating across oncology, immunology, and rare diseases, with significant antibody therapeutics franchises and a stated interest in nanobody-based modalities. It represents both a competitor and a potential licensing/partnering counterpart for nanobody platforms.
- Regeneron: Regeneron is a leading antibody-based biopharmaceutical company with VelocImmune, VelociBi, and bispecific antibody platforms. Its therapeutic antibodies (e.g., Dupixent, Libtayo) overlap with Ablynx's immunology and oncology focus and represent large-scale commercial benchmarks.
- Roche / Genentech: Roche and its Genentech subsidiary are the world's largest developers of therapeutic monoclonal antibodies, with broad bispecific and antibody-drug conjugate programs. They compete with Ablynx's nanobody platform across the same therapeutic indications and represent the dominant commercial benchmark in biologic therapeutics.
Emerging players
- AbCellera Biologics: AbCellera operates an antibody discovery platform partnering with pharma companies to identify clinical-grade antibody therapeutics, with overlapping capability in AI-driven and high-throughput antibody engineering comparable to Ablynx's discovery infrastructure.
- Adimab: Adimab is a technology-focused antibody discovery company that partners with biopharmaceutical firms to identify therapeutic antibodies. It shares Ablynx's platform-discovery business model but uses conventional yeast-based antibody libraries rather than camelid-derived scaffolds.
- Harbour BioMed: Harbour BioMed develops therapeutics using heavy-chain-only antibody (HCAb) technology derived from transgenic mice, a closely related single-domain antibody approach to Ablynx's NANOBODY platform. It targets immuno-oncology and immunology indications with a similar modality.
- Ossianix: Ossianix is a preclinical-stage biopharma developing single-domain VNAR antibody therapeutics from sharks, directly comparable to Ablynx's use of shark-derived heavy-chain-only antibodies for therapeutic discovery.
Others
- Sanofi (parent): Sanofi is Ablynx's strategic parent company following the 2018 acquisition, integrating the NANOBODY platform into its broader immunology, oncology, and rare disease pipeline. It is the principal commercialization and manufacturing partner for nanobody-based therapeutics originated by Ablynx.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Ablynx social profiles
Digital presenceAblynx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ablynx leadership team
Management profileNumber of profiles
Profiles6 records
Ablynx funding detail
Funding detailFunding overview
Funding rounds8 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ablynx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ablynx
What does Ablynx do?
Ablynx developed and commercialized the proprietary NANOBODY® technology platform, a single-domain antibody fragment technology derived from heavy-chain only antibodies found in camelids (camels, llamas, alpacas) and sharks. The platform enables the engineering of multivalent nanobody molecules that can bind multiple therapeutic targets at once, supporting development of orally bioavailable treatments for immune-mediated diseases (e.g., chronic immune thrombocytopenia) and oncology, including bispecific constructs that bridge tumor cells with immune cells.
Is Ablynx a public or private company?
Ablynx is a private company. It is classified as corporate owned and is currently acquired.
When was Ablynx founded?
Ablynx was founded in 2001. It employs 251 to 500 people.
Where is Ablynx based?
Ablynx is headquartered in Zwijnaarde, Belgium, in the Europe region.
Who are Ablynx's main competitors?
Direct peers on record are argenx and Genmab. Broad incumbents are AstraZeneca, Regeneron and Roche / Genentech. Emerging players are AbCellera Biologics, Adimab, Harbour BioMed and Ossianix. Sanofi (parent) is listed as an others.
Does Ablynx have an API?
No public API is recorded for Ablynx.
What industry is Ablynx in?
Ablynx's product category is Biopharmaceuticals / Nanobody Therapeutics. Its primary akta.pro industry code is HLAAAAAG, Nanobodies & Alternative Antibody Scaffolds, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.